Drug intelligence / Profile preview

JMIT-HT11

Development stage: Unknown
Lead developer: Jianmin Pharmaceutical Group

Overview

JMIT-HT11 is an investigational drug candidate under development by Jianmin Pharmaceutical Group for the treatment of infertility. It is part of the company's non-pediatric pipeline, as indicated by its 'JMIT' prefix. According to the developer's R&D pipeline, the drug has advanced into clinical development, specifically Phase 1 trials. Detailed information regarding its molecular target, modality, and specific mechanism of action has not been publicly disclosed by Jianmin Pharmaceutical Group.

Beyond the preview

Go deeper on JMIT-HT11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMIT-HT11.

Explore the full profile